Results 71 to 80 of about 26,399 (169)

T cell toxicity of HIV latency reversing agents

Pharmacological Research, 2019
Combination antiretroviral therapy reduces morbidity and mortality in HIV infected patients. However, the cure of HIV infection is hindered by the persistence of the latent HIV reservoir. Latency reversing agents (LRAs) are developed to target the HIV latently infected cells for HIV reactivation.
Zhao, Manzhi, Crignis, Elisa, Rokx, Casper, Verbon, Annelies, Gelder, Teun, Mahmoudi, Tokameh, Katsikis, Peter, Müller, Yvonne   +7 more
openaire   +2 more sources

Targeting Latent HIV Reservoirs: Effectiveness of Combination Therapy with HDAC and PARP Inhibitors

Viruses
The “Kick and Kill” strategy, which aims to reactivate latent HIV reservoirs and facilitate the clearance of reactivated HIV-infected cells, has yet to achieve a functional cure due to the limited efficacy of current latency reversal agents.
Hasset Tibebe, Dacia Marquez, Aidan McGraw, Sophia Gagliardi, Cailyn Sullivan, Grace Hillmer, Kedhar Narayan, Coco Izumi, Adleigh Keating, Taisuke Izumi   +9 more
doaj   +1 more source

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

PLOS Pathogens, 2015
Pharmacologically-induced activation of replication competent proviruses from latency in the presence of antiretroviral treatment (ART) has been proposed as a step towards curing HIV-1 infection. However, until now, approaches to reverse HIV-1 latency in humans have yielded mixed results.
Søgaard, OS, Graversen, ME, Leth, S, Olesen, R, Brinkmann, CR, Nissen, SK, Kjaer, AS, Schleimann, MH, Denton, PW, Hey-Cunningham, WJ, Koelsch, KK, Pantaleo, G, Krogsgaard, K, Sommerfelt, M, Fromentin, R, Chomont, N, Rasmussen, TA, Østergaard, L, Tolstrup, M   +18 more
openaire   +8 more sources

HIV Tat as a latency reversing agent: turning the tables on viral persistence

Frontiers in Immunology
The ‘shock and kill’ approach to an HIV cure involves the use of latency reversing agents (LRAs) to reactivate latent HIV, with the aim to induce death of infected cells through virus induced cytolysis or immune mediated clearance.
Bridget M. Fisher, Paula M. Cevaal, Michael Roche, Michael Roche, Sharon R. Lewin, Sharon R. Lewin, Sharon R. Lewin   +6 more
doaj   +1 more source

Latency-Reversing Agents Induce Differential Responses in Distinct Memory CD4 T Cell Subsets in Individuals on Antiretroviral Therapy

Cell Reports, 2019
Summary: Latent proviruses persist in central (TCM), transitional (TTM), and effector (TEM) memory cells. We measured the levels of cellular factors involved in HIV gene expression in these subsets.
Marion Pardons, Rémi Fromentin, Amélie Pagliuzza, Jean-Pierre Routy, Nicolas Chomont   +4 more
doaj   +1 more source

Comparison of different protocols of Morris water maze in cognitive impairment with heart failure

Brain and Behavior, 2020
Aim This study aimed to find a more sensitive and systematic behavioral evaluation protocol to evaluate the cognitive impairment in rats with heart failure (HF).
Ziwen Lu, Tao Yang, Lei Wang, Qi Qiu, Yizhou Zhao, Aiming Wu, Tong Li, Wenkun Cheng, Baofu Wang, Yang Li, Jingjing Yang, Mingjing Zhao   +11 more
doaj   +1 more source

Reanalysis of Gene Expression Profiles of CD4+ T Cells Treated with HIV-1 Latency Reversal Agents [PDF]

, 2020
The human immunodeficiency virus (HIV-1) causes a progressive depletion of CD4+ T cells, hampering immune function. Current experimental strategies to fight the virus focus on the reactivation of latent HIV-1 in the viral reservoir to make the virus ...
Sergio Crovella, Moura, Ronald Rodrigues de, Antonio Victor Campos Coelho, Ronald Rodrigues de Moura, Crovella, Sergio, Campos Coelho, Antonio Victor   +5 more
core   +1 more source

Correlation of pattern reversal visual evoked potential parameters with the pattern standard deviation in primary open angle glaucoma [PDF]

International Journal of Ophthalmology, 2014
AIM:To evaluate whether glaucomatous visual field defect particularly the pattern standard deviation (PSD) of Humphrey visual field could be associated with visual evoked potential (VEP) parameters of patients having primary open angle glaucoma (POAG ...
Ruchi Kothari, Pradeep Bokariya, Ramji Singh, Smita Singh, Purvasha Narang   +4 more
doaj   +1 more source

Correction for Garrido et al., “Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo”

, 2020
Correction to “Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex ...
Soriano-Sarabia, Natalia, Margolis, David M., Ferrari, Guido, Tuyishime, Marina, Abad-Fernandez, Maria, Garrido, Carolina, Pollara, Justin J.   +6 more
core   +1 more source

The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells

JCI Insight, 2023
IL-15 is under clinical investigation toward the goal of curing HIV infection because of its abilities to reverse HIV latency and enhance immune effector function. However, increased potency through combination with other agents may be needed.
Dennis C. Copertino Jr., Carissa S. Holmberg, Jared Weiler, Adam R. Ward, J. Natalie Howard, Callie Levinger, Alina P.S. Pang, Michael J. Corley, Friederike Dündar, Paul Zumbo, Doron Betel, Rajesh T. Gandhi, Deborah K. McMahon, Ronald J. Bosch, Noemi Linden, Bernard J. Macatangay, Joshua C. Cyktor, Joseph J. Eron, John W. Mellors, Colin Kovacs, Erika Benko, Alberto Bosque, R. Brad Jones, for the AIDS Clinical Trials Group (ACTG) A5321 Team   +23 more
doaj   +1 more source